{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T18:28:40Z","timestamp":1793557720518,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Chromophobe renal cell carcinoma (chRCC) is a rare subtype of renal cell carcinoma (RCC) and is the most common form of non-clear cell renal cell carcinoma in young women. Compared to clear cell renal cell carcinoma (ccRCC), chRCC usually has an excellent prognosis, indicating the need for a reliable differential diagnosis, especially to distinguish it from eosinophilic variants of ccRCC. Another important differential diagnosis is renal oncocytoma (RO), which remains a major challenge even for experienced pathologists. The treatment of RO typically involves active surveillance, with surgical resection indicated if there is significant tumor growth. In contrast, for chRCC, the approach depends on tumor size, with either partial or radical nephrectomy being required. This review therefore summarizes key unique features and recent findings on this tumor, aiming to ensure a reliable differential diagnosis, thereby facilitating appropriate treatment selection and prognosis assessment. The histology of chRCC, including both for the classic and the eosinophilic subtype, is characterized by the appearance of raisinoid cell nuclei with perinuclear halos on microscopic imaging. In rare cases, signs of sarcomatoid, glandular and\/or anaplastic dedifferentiation can also be observed, which significantly worsens the prognosis. The immunohistochemical marker phospho-S6 can be used to detect these changes. In addition to other routinely used markers such as C-Kit, CK7, EpCAM, CAIX and Claudin 7, we recommend the use of progesterone receptors as markers, as many chRCC express them and are thus progesterone-sensitive. This progesterone sensitivity could indicate that chRCC, similar to breast cancer, may represent a contraindication for the use of hormonal contraceptives. In addition to immunohistochemistry, molecular features of chRCC such as genetic, epigenetic, transcriptomic and proteomic alterations can be considered in the differential diagnosis. In this review, we therefore outline the most important established alterations in this context. In the treatment of metastatic chRCC, checkpoint inhibitors and tyrosine kinase inhibitors have demonstrated efficacy and may represent a promising new approach for managing dedifferentiated, aggressive or metastatic chRCC. This review aims to present recent therapeutic advances and provide innovative approaches for future clinical treatment decisions.<\/jats:p>","DOI":"10.1186\/s12894-025-01816-5","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T18:51:46Z","timestamp":1748890306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Chromophobe renal cell carcinoma \u2013 a rare kidney cancer with limited therapy options: a narrative review"],"prefix":"10.1186","volume":"25","author":[{"given":"Milad","family":"Pashai Fakhri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Serth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Hinrich","family":"Br\u00e4sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Ivanyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus Antonius","family":"Kuczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Tezval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"1816_CR1","doi-asserted-by":"publisher","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. (2025) Cancer statistics, 2025 https:\/\/doi.org\/10.3322\/caac.21871","DOI":"10.3322\/caac.21871"},{"key":"1816_CR2","doi-asserted-by":"publisher","unstructured":"Daugherty M, Blakely S, Shapiro O, Vourganti S, Mollapour M, Bratslavsky G. Chromophobe renal cell carcinoma is the most common nonclear renal cell carcinoma in young women: results from the SEER database. J Urol. 2016;195(4 Part 1):847\u201351. https:\/\/doi.org\/10.1016\/j.juro.2015.10.177.","DOI":"10.1016\/j.juro.2015.10.177"},{"key":"1816_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2019.06.011","author":"J Casuscelli","year":"2019","unstructured":"Casuscelli J, Becerra MF, Seier K, Manley BJ, Benfante N, Redzematovic A, Stief CG, Hsieh JJ, Tickoo SK, Reuter VE, Coleman JA, Russo P, Ostrovnaya I, Hakimi AA. Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series. 2019. https:\/\/doi.org\/10.1016\/j.clgc.2019.06.011.","journal-title":"Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series"},{"key":"1816_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.09.036","author":"NE Hoffmann","year":"2008","unstructured":"Hoffmann NE, Gillett MD, Cheville JC, Lohse CM, Leibovich BC, Blute ML. Differences in organ system of distant metastasis by renal cell carcinoma subtype. 2008. https:\/\/doi.org\/10.1016\/j.juro.2007.09.036.","journal-title":"Differences in organ system of distant metastasis by renal cell carcinoma subtype"},{"key":"1816_CR5","doi-asserted-by":"publisher","DOI":"10.1053\/j.semdp.2024.01.008","author":"J Wu","year":"2024","unstructured":"Wu J, Lu J, Wu CL, Lu M. Birt-Hogg-Dub\u00e9 syndrome in an overall view: Focus on the clinicopathological prospects in renal tumors. 2024. https:\/\/doi.org\/10.1053\/j.semdp.2024.01.008.","journal-title":"Birt-Hogg-Dub\u00e9 syndrome in an overall view: Focus on the clinicopathological prospects in renal tumors"},{"key":"1816_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103287","author":"R Garje","year":"2021","unstructured":"Garje R, Elhag D, Yasin HA, Acharya L, Vaena D, Dahmoush L. Comprehensive review of chromophobe renal cell carcinoma. 2021. https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103287.","journal-title":"Comprehensive review of chromophobe renal cell carcinoma"},{"key":"1816_CR7","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2021200206","author":"J Marko","year":"2021","unstructured":"Marko J, Craig R, Nguyen A, Udager AM, Wolfman DJ. Chromophobe Renal Cell Carcinoma with Radiologic-Pathologic Correlation. 2021. https:\/\/doi.org\/10.1148\/rg.2021200206.","journal-title":"Chromophobe Renal Cell Carcinoma with Radiologic-Pathologic Correlation"},{"key":"1816_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2020.09.015","author":"H Moch","year":"2021","unstructured":"Moch H, Ohashi R. Chromophobe renal cell carcinoma: current and controversial issues. 2021. https:\/\/doi.org\/10.1016\/j.pathol.2020.09.015.","journal-title":"Chromophobe renal cell carcinoma: current and controversial issues"},{"key":"1816_CR9","doi-asserted-by":"publisher","unstructured":"L\u00fcders C, Kristiansen G. (2016) Onkozytom versus chromophobes Nierenkarzinom: Gibt es etwas dazwischen? https:\/\/doi.org\/10.1007\/s00292-016-0145-0","DOI":"10.1007\/s00292-016-0145-0"},{"key":"1816_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajur.2021.11.010","author":"R Alaghehbandan","year":"2022","unstructured":"Alaghehbandan R, Przybycin CG, Verkarre V, Mehra R. Chromophobe renal cell carcinoma: Novel molecular insights and clinicopathologic updates. 2022. https:\/\/doi.org\/10.1016\/j.ajur.2021.11.010.","journal-title":"Chromophobe renal cell carcinoma: Novel molecular insights and clinicopathologic updates"},{"key":"1816_CR11","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.176743","author":"P Kapur","year":"2024","unstructured":"Kapur P, Zhong H, Le D, Mukhopadhyay R, Miyata J, Carrillo D, Rakheja D, Rajaram S, Durinck S, Modrusan Z, Brugarolas J. Molecular underpinnings of dedifferentiation and aggressiveness in chromophobe renal cell carcinoma. 2024. https:\/\/doi.org\/10.1172\/jci.insight.176743.","journal-title":"Molecular underpinnings of dedifferentiation and aggressiveness in chromophobe renal cell carcinoma"},{"key":"1816_CR12","doi-asserted-by":"publisher","unstructured":"Liu L, Qian J, Singh H, Meiers I, Zhou X. (2007) Bostwick DG Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis https:\/\/doi.org\/10.5858\/2007-131-1290-IAOCRC","DOI":"10.5858\/2007-131-1290-IAOCRC"},{"key":"1816_CR13","doi-asserted-by":"publisher","unstructured":"Jiang J, Yang L, Chen M, Xiao F, Zeng, Zhu H, Li Y, Liu L. Smoking enhanced the expression of c-kit in chromophobe renal cell carcinoma.\u00a02023. https:\/\/doi.org\/10.18332\/id\/170432.","DOI":"10.18332\/id\/170432"},{"key":"1816_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2007.02931.x","author":"KT Mai","year":"2008","unstructured":"Mai KT, Teo I, Belanger EC, Robertson SJ, Marginean EC, Islam S. Progesterone receptor reactivity in renal oncocytoma and chromophobe renal cell carcinoma. 2008. https:\/\/doi.org\/10.1111\/j.1365-2559.2007.02931.x.","journal-title":"Progesterone receptor reactivity in renal oncocytoma and chromophobe renal cell carcinoma"},{"key":"1816_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-024-01314-2","author":"S Liu","year":"2024","unstructured":"Liu S, Hou M, Yao Y, Mei J, Sun L, Zhang G. External validation of a four-tiered grading system for chromophobe renal cell carcinoma. 2024. https:\/\/doi.org\/10.1007\/s10238-024-01314-2.","journal-title":"External validation of a four-tiered grading system for chromophobe renal cell carcinoma"},{"key":"1816_CR16","doi-asserted-by":"publisher","unstructured":"Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, Shen H, Buhay C, Kang H, Kim SC, Fahey CC, Hacker KE, Bhanot G, Gordenin DA, Chu A, Gunaratne PH, Biehl M, Seth S, Kaipparettu BA, Bristow CA, Donehower LA, Wallen EM, Smith AB, Tickoo SK, Tamboli P, Reuter V, Schmidt LS, Hsieh JJ, Choueiri TK, Hakimi AA; The\u00a0Cancer Genome Atlas Research Network; Chin L., Meyerson M., Kucherlapati R., Park WY., Robertson AG., Laird PW., Henske EP., Kwiatkowski DJ., Park PJ., Morgan M., Shuch B., Muzny D., Wheeler DA., Linehan WM., Gibbs RA., Rathmell WK., Creighton CJ. (2014) The somatic genomic landscape of chromophobe renal cell carcinoma https:\/\/doi.org\/10.1016\/j.ccr.2014.07.014","DOI":"10.1016\/j.ccr.2014.07.014"},{"key":"1816_CR17","doi-asserted-by":"publisher","unstructured":"Alaghehbandan R, Siadat F, Trpkov K (2023) What's new in the WHO 2022 classification of kidney tumours? https:\/\/doi.org\/10.32074\/1591-951X-818","DOI":"10.32074\/1591-951X-818"},{"key":"1816_CR18","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2016.4198","author":"WH Weng","year":"2016","unstructured":"Weng WH, Chen YT, Yu KJ, Chang YH, Chuang CK, Pang ST. Genetic alterations of HER genes in chromophobe renal cell carcinoma. 2016. https:\/\/doi.org\/10.3892\/ol.2016.4198.","journal-title":"Genetic alterations of HER genes in chromophobe renal cell carcinoma"},{"key":"1816_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.arcmed.2022.11.003","author":"F Recillas-Targa","year":"2022","unstructured":"Recillas-Targa F. Cancer Epigenetics: An Overview. 2022. https:\/\/doi.org\/10.1016\/j.arcmed.2022.11.003.","journal-title":"Cancer Epigenetics: An Overview"},{"key":"1816_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01851-y","author":"X Chu","year":"2024","unstructured":"Chu X, Tian W, Ning J, Xiao G, Zhou Y, Wang Z, Zhai Z, Tanzhu G, Yang J, Zhou R. Cancer stem cells: advances in knowledge and implications for cancer therapy. 2024. https:\/\/doi.org\/10.1038\/s41392-024-01851-y.","journal-title":"Cancer stem cells: advances in knowledge and implications for cancer therapy"},{"key":"1816_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/nrg1748","author":"AP Feinberg","year":"2006","unstructured":"Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. 2006. https:\/\/doi.org\/10.1038\/nrg1748.","journal-title":"The epigenetic progenitor origin of human cancer"},{"key":"1816_CR22","doi-asserted-by":"publisher","unstructured":"Faraj Tabrizi P, Peters I, Schimansky I, Dubrowinskaja N, Reese C, Tezval H, Kuczyk MA, Serth J. (2023) Alteration of Cadherin 3 Expression and DNA Methylation in Association with Aggressive Renal Cell Carcinoma https:\/\/doi.org\/10.3390\/ijms242216476","DOI":"10.3390\/ijms242216476"},{"key":"1816_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.08.034","author":"TX Lu","year":"2018","unstructured":"Lu TX, Rothenberg ME. MicroRNA. 2018. https:\/\/doi.org\/10.1016\/j.jaci.2017.08.034.","journal-title":"MicroRNA"},{"key":"1816_CR24","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S116392","author":"HT He","year":"2016","unstructured":"He HT, Xu M, Kuang Y, Han XY, Wang MQ, Yang Q. Biomarker and competing endogenous RNA potential of tumor-specific long noncoding RNA in chromophobe renal cell carcinoma. 2016. https:\/\/doi.org\/10.2147\/OTT.S116392.","journal-title":"Biomarker and competing endogenous RNA potential of tumor-specific long noncoding RNA in chromophobe renal cell carcinoma"},{"key":"1816_CR25","doi-asserted-by":"publisher","unstructured":"Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. (2011) A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language? https:\/\/doi.org\/10.1016\/j.cell.2011.07.014","DOI":"10.1016\/j.cell.2011.07.014"},{"key":"1816_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cells11020287","author":"KB Satter","year":"2022","unstructured":"Satter KB, Tran PMH, Tran LKH, Ramsey Z, Pinkerton K, Bai S, Savage NM, Kavuri S, Terris MK, She JX, Purohit S. Oncocytoma-Related Gene Signature to Differentiate Chromophobe Renal Cancer and Oncocytoma Using. Mach Learn. 2022. https:\/\/doi.org\/10.3390\/cells11020287.","journal-title":"Mach Learn"},{"key":"1816_CR27","unstructured":"GeneCards \u2013 the human gene database (www.genecards.org) The GeneCards Suite: From GeneData Mining to Disease Genome Sequence Analyses (PMID: 27322403 ; Citations: 3,096 ) StelzerG, Rosen R, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, Iny Stein T, Nudel R, Lieder I, Mazor Y, Kaplan S, Dahary, D, Warshawsky D, Guan - Golan Y, Kohn A, Rappaport N, Safran M, and Lancet D. Current Protocols in Bioinformatics. 2016;54:1.30.1 - 1.30.33.10.1002 \/ cpbi.5 [PDF]"},{"key":"1816_CR28","doi-asserted-by":"publisher","unstructured":"Wu Y, Miyamoto T, Li K, Nakagomi H, Sawada N, Kira S, Kobayashi H, Zakohji H, Tsuchida T, Fukazawa M, Araki I, Takeda M. (2011) Decreased expression of the epithelial Ca2+ channel TRPV5 and TRPV6 in human renal cell carcinoma associated with vitamin D receptor https:\/\/doi.org\/10.1016\/j.juro.2011.07.086","DOI":"10.1016\/j.juro.2011.07.086"},{"key":"1816_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s12014-023-09443-8","author":"LB Carvalho","year":"2023","unstructured":"Carvalho LB, Jorge S, L\u00f3pez-Fern\u00e1ndez H, Lodeiro C, Dhir R, Campos Pinheiro L, Medeiros M, Santos HM, Capelo JL. Proteomic analysis of chromophobe renal cell carcinoma and benign renal oncocytoma biopsies reveals shared metabolic dysregulation. 2023. https:\/\/doi.org\/10.1186\/s12014-023-09443-8.","journal-title":"Proteomic analysis of chromophobe renal cell carcinoma and benign renal oncocytoma biopsies reveals shared metabolic dysregulation"},{"key":"1816_CR30","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-1998","author":"Y Xiao","year":"2020","unstructured":"Xiao Y, Rabien A, Buschow R, Amtislavskiy V, Busch J, Kilic E, Villegas SL, Timmermann B, Sch\u00fctte M, Mielke T, Yaspo ML, Jung K, Meierhofer D. Endocytosis-Mediated Replenishment of Amino Acids Favors Cancer Cell Proliferation and Survival in Chromophobe Renal Cell Carcinoma. 2020. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-1998.","journal-title":"Endocytosis-Mediated Replenishment of Amino Acids Favors Cancer Cell Proliferation and Survival in Chromophobe Renal Cell Carcinoma"},{"key":"1816_CR31","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.22413","author":"G K\u00fcrschner","year":"2017","unstructured":"K\u00fcrschner G, Zhang Q, Clima R, Xiao Y, Busch JF, Kilic E, Jung K, Berndt N, Bulik S, Holzh\u00fctter HG, Gasparre G, Attimonelli M, Babu M, Meierhofer D. Renal oncocytoma characterized by the defective complex I of the respiratory chain boosts the synthesis of the ROS scavenger glutathione. 2017. https:\/\/doi.org\/10.18632\/oncotarget.22413.","journal-title":"Renal oncocytoma characterized by the defective complex I of the respiratory chain boosts the synthesis of the ROS scavenger glutathione"},{"key":"1816_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2015.10.059","author":"S Joshi","year":"2015","unstructured":"Joshi S, Tolkunov D, Aviv H, Hakimi AA, Yao M, Hsieh JJ, Ganesan S, Chan CS, White E. The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis. 2015. https:\/\/doi.org\/10.1016\/j.celrep.2015.10.059.","journal-title":"The Genomic Landscape of Renal Oncocytoma Identifies a Metabolic Barrier to Tumorigenesis"},{"key":"1816_CR33","doi-asserted-by":"publisher","unstructured":"Ju YS, Alexandrov LB, Gerstung M, Martincorena I, Nik-Zainal S, Ramakrishna M, Davies HR, Papaemmanuil E, Gundem G, Shlien A, Bolli N, Behjati S, Tarpey PS, Nangalia J, Massie CE, Butler AP, Teague JW, Vassiliou GS, Green AR, Du MQ, Unnikrishnan A, Pimanda JE, Teh BT, Munshi N, Greaves M, Vyas P, El-Naggar AK, Santarius T, Collins VP, Grundy R, Taylor JA, Hayes DN, Malkin D; ICGC Breast Cancer Group; ICGC Chronic Myeloid Disorders Group; ICGC Prostate Cancer Group; Foster CS, Warren AY, Whitaker HC, Brewer D, Eeles R, Cooper C, Neal D, Visakorpi T, Isaacs WB, Bova GS, Flanagan AM, Futreal PA, Lynch AG, Chinnery PF, McDermott U, Stratton MR, Campbell PJ (2014). Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer https:\/\/doi.org\/10.7554\/eLife.02935","DOI":"10.7554\/eLife.02935"},{"key":"1816_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2014.12.003","author":"AS Tan","year":"2015","unstructured":"Tan AS, Baty JW, Dong LF, Bezawork-Geleta A, Endaya B, Goodwin J, Bajzikova M, Kovarova J, Peterka M, Yan B, Pesdar EA, Sobol M, Filimonenko A, Stuart S, Vondrusova M, Kluckova K, Sachaphibulkij K, Rohlena J, Hozak P, Truksa J, Eccles D, Haupt LM, Griffiths LR, Neuzil J, Berridge MV. Mitochondrial genome acquisition restores respiratory function and tumorigenic potential of cancer cells without mitochondrial. DNA. 2015. https:\/\/doi.org\/10.1016\/j.cmet.2014.12.003.","journal-title":"DNA"},{"key":"1816_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1325999","author":"H Zhang","year":"2024","unstructured":"Zhang H, Cong X, Chen C, Liu Z. Sintilimab combined with axitinib in the treatment of advanced chromophobe renal cell carcinoma: a case report. 2024. https:\/\/doi.org\/10.3389\/fonc.2024.1325999.","journal-title":"Sintilimab combined with axitinib in the treatment of advanced chromophobe renal cell carcinoma: a case report"},{"key":"1816_CR36","doi-asserted-by":"publisher","unstructured":"Rexer H, Bergmann L, Steiner T. (2020) A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma - SUNNIFORECAST AN 41\/16 der AUO https:\/\/doi.org\/10.1055\/a-1079-7621","DOI":"10.1055\/a-1079-7621"},{"key":"1816_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s00292-016-0171-y","author":"H Moch","year":"2016","unstructured":"Moch H. The WHO\/ISUP grading system for renal carcinoma. 2016. https:\/\/doi.org\/10.1007\/s00292-016-0171-y.","journal-title":"The WHO\/ISUP grading system for renal carcinoma"},{"key":"1816_CR38","doi-asserted-by":"publisher","unstructured":"Lopez-Beltran A, Montironi R, Cimadamore A, Cheng L. (2021) Grading of Chromophobe Renal Cell Carcinoma: Do We Need It? https:\/\/doi.org\/10.1016\/j.eururo.2020.11.001","DOI":"10.1016\/j.eururo.2020.11.001"},{"issue":"9","key":"1816_CR39","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1097\/PAS.0b013e3181e96f2a","volume":"34","author":"GP Paner","year":"2010","unstructured":"Paner GP, Amin MB, Alvarado-Cabrero I, Young AN, Stricker HJ, Moch H, Lyles RH. A novel tumor grading scheme for chromophobe renal cell carcinoma. Am J Surg Pathol. 2010;34(9):1233\u201340. https:\/\/doi.org\/10.1097\/PAS.0b013e3181e96f2a.","journal-title":"Am J Surg Pathol."},{"key":"1816_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.10.007","author":"S Avulova","year":"2021","unstructured":"Avulova S, Cheville JC, Lohse CM, Gupta S, Potretzke TA, Tsivian M, Thompson RH, Boorjian SA, Leibovich BC, Potretzke AM. Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis. 2021. https:\/\/doi.org\/10.1016\/j.eururo.2020.10.007.","journal-title":"Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis"},{"key":"1816_CR41","doi-asserted-by":"publisher","unstructured":"Piccinelli ML, Morra S, Tappero S, Cano Garcia C, Barletta F, Incesu RB, Scheipner L, Baudo A, Tian Z, Luzzago S, Mistretta FA, Ferro M, Saad F, Shariat SF, Carmignani L, Ahyai S, Tilki D, Briganti A, Chun FKH, Terrone C, Longo N, de Cobelli O, Musi G, Karakiewicz PI. (2023) Critical Appraisal of Leibovich 2018 and GRANT Models for Prediction of Cancer-Specific Survival in Non-Metastatic Chromophobe Renal Cell Carcinoma https:\/\/doi.org\/10.3390\/cancers15072155","DOI":"10.3390\/cancers15072155"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01816-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-025-01816-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-025-01816-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T18:51:47Z","timestamp":1748890307000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcurol.biomedcentral.com\/articles\/10.1186\/s12894-025-01816-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1816"],"URL":"https:\/\/doi.org\/10.1186\/s12894-025-01816-5","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]},"assertion":[{"value":"12 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"147"}}